drugset / Trial / NCT00610857
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
NaSingle-groupOpen-labelOther
Summary
To determine the safety and efficacy of the combination of HDI and anti-CTLA-4 monoclonal antibody for patients with recurrent inoperable stage III or stage IV melanoma.
Timeline
- Start
- 2006-11
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tremelimumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 10 unknown | Intravenous |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 20 unknown | Intravenous |